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Aim: To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the
agreement in treatment decisions between hospitals from 4 European countries for the same patient
cohort.
Methods: Breast cancer patients were prospectively enrolled and MammaPrint was assessed. Patients’
clinical data without and then with MammaPrint results were sent to the different multidisciplinary
teams and treatment advice was provided for each patient.
Results: Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancer patients was
changed in 37% of patients by the Dutch, 24% by the Belgian, 28% by the Italian and 35% by the Spanish
teams. MammaPrint increased the inter-institutional agreement in treatment advice (chemotherapy or
no chemotherapy) from 51% to 75%.
Conclusion: The results of this study indicate that MammaPrint impacts adjuvant chemotherapy
recommendation. MammaPrint can decrease inter-institutional and inter-country variability in adjuvant
treatment advice for breast cancer patients.
 2014 Elsevier Ltd. All rights reserved.Introduction
Breast cancer is the second most common cancer in Europe
(data from 40 countries), comprising 13.1% of all cancers [1]. In
2008, the estimated age-adjusted annual incidence of breast cancer
in Europe was 88.4/100,000 and the mortality rate was 24.3/
100,000 [1]. Breast cancer is the main cause of cancer death in
women in Europe [2] and worldwide [3]. The incidence of breast
cancer is increasing due to a number of factors, including improved
diagnosis as a result of the expanded use of mammographic
screening, an aging population [4], postmenopausal hormone
replacement therapy [4,5], obesity [4,6] and alcohol [7] and tobacco
consumption [8,9].Tilman, Avenue de l’Hôpital,
B 35, 4000 Liège 1, Belgium.
ano.be (P.G. Cusumano).Systemic adjuvant treatment can decrease the rate of recurrence
and improve survival in patients with early-stage resected breast
cancer [10]. Adjuvant treatment includes chemotherapy, hormonal
therapy, combined chemotherapy plus hormonal therapy and tar-
geted therapy such as trastuzumab [10]. Treatment recommenda-
tions are based on the patient’s risk of recurrence, the benefits and
potential adverse effects of therapy and the patient’s preference.
Factors that affect the risk of tumor recurrence include the estrogen
receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) overexpression status, tumor size
and grade, the presence of lymphovascular invasion, lymph node
metastasis and the proliferation index [11].
The 70-gene tumor expression profile MammaPrint classifies
patients as Low Risk or High Risk for the development of distant
metastases. MammaPrint has been shown to be a powerful pre-
dictor of disease outcome in breast cancer in a number of studies
[12e18]. The 2013 St Gallen International Expert Consensus on the
primary therapy of early breast cancer include gene-expression
signatures as an indicator for adjuvant therapy [19]. In addition,
P.G. Cusumano et al. / The Breast 23 (2014) 423e428424the use of MammaPrint to obtain additional prognostic and/or
predictive information for risk assessment and to predict the
benefit of adjuvant chemotherapy is included in the European So-
ciety for Medical Oncology (ESMO) practice guidelines for primary
breast cancer [2]. Inter-institutional differences in the interpreta-
tion of prognostic and predictive factors and in the quality of
immunohistochemistry (IHC) analysis [20e23] can substantially
affect the adjuvant treatment advice provided, resulting in the risk
of potential over or under treatment [24]. The introduction of a
centralized multi-gene assay could potentially lead to more
formalized and standardized treatment recommendations
throughout Europe.
In the prospective multi-center microarRAy prognoSTics in
breast cancER (RASTER) study the clinical impact on adjuvant sys-
temic therapy decision making was assessed [12]. A considerable
discrepancy in risk estimations among different clinicopathologic
guidelines and MammaPrint was observed. The addition of Mam-
maPrint to standard clinicopathological factors led to a change in
adjuvant systemic treatment advice in 19% of patients [12]. After a
median follow-up of 61.6 months, 15% (33/219) of MammaPrint
Low Risk patients received adjuvant chemotherapy versus 81%
(169/208) of MammaPrint High Risk patients. In a follow-up anal-
ysis, the 5-year distant-recurrence-free-interval probabilities for
MammaPrint Low Risk (n ¼ 219) and High Risk (n ¼ 208) patients
were 97% and 92%, respectively [18]. The decision not to use
adjuvant chemotherapy based on a Low-Risk MammaPrint result,
did not appear to affect patient outcomes.
The current study measured the impact of MammaPrint on
adjuvant treatment decisions in four European countries and
analyzed the agreement in adjuvant treatment decisions between
four European hospitals for the same patient cohort.
Patients and methods
Study design
Eligible patients were consecutively enrolled from three hospi-
tals in the Netherlands, Belgium and Italy. Clinicopathological data
was assembled and MammaPrint assessed. Patients’ clinical data
without the MammaPrint results from one country were sent to
multidisciplinary teams at two hospitals in the other two countries
(e.g. data from the Netherlands was sent to Belgium and Italy) plus
a fourth hospital in Spain and adjuvant treatment advice was
provided for each patient. Subsequently, patients’ clinical data
including the MammaPrint results were sent to the same multi-
disciplinary teams and adjuvant treatment advice was again pro-
vided for each patient.
The impact of MammaPrint on chemotherapy treatment
advice was assessed for each hospital. Furthermore the inter-
institutional agreement which is defined as the agreement in
adjuvant treatment decisions between hospitals for the same
patient cohort.
Study objectives
To investigate the impact of MammaPrint on adjuvant chemo-
therapy treatment advice as determined by the multidisciplinary
teams at four European hospitals and to assess the agreement in
adjuvant treatment decisions for the same patient cohort between
European hospitals.
Patients
Women (aged 18e70 years) with histologically proven, oper-
able, unilateral, invasive breast cancer and sentinel node or axillaryclearance (T1e3, N0e1, M0) and a successful MammaPrint were
eligible for inclusion.Written informed consent was provided by all
patients prior to their participation in the study.
MammaPrint
MammaPrint was performed on fresh tumor samples obtained
from surgical specimens (minimum 3 mm3 tumor tissue) or core
needle biopsies (two cores of tumor tissue from a 14-gauge or one
core from a 10e12-gauge needle). Microarray analysis for obtaining
the profiles was performed at the centralized Agendia Laboratories
blinded for clinical and pathological data [25].
ER, progesterone receptor (PR) and HER2 IHC/fluorescence in situ
hybridization (FISH) assessments
IHC/FISH assessments were performed according to local stan-
dards at each institution. The threshold for ER and PR was set at 1%
positive staining. HER2 3þ was considered to be positive with a
threshold of 10% positive staining. HER2 2 þ cases were assessed
by FISH.
Results
MammaPrint results were prospectively collected from 194
patients in the Netherlands (n ¼ 66), Belgium (n ¼ 92) and Italy
(n ¼ 36). Patients’ clinical characteristics are shown in Table 1. The
majority of patients (86%) were ERþ and HER2 (88%). 85 (44%)
patients were MammaPrint Low Risk and 109 (56%) were Mam-
maPrint High Risk. The decision by the multidisciplinary teams
whether or not to advise adjuvant chemotherapy, without and then
with the MammaPrint results, is shown in Table 2. Without
knowing the MammaPrint results 97/128 (76%) of patients were
advised adjuvant chemotherapy by the Dutch team. After knowing
the MammaPrint results there was a 14% decrease in adjuvant
chemotherapy treatment advice (79/128 62%). Overall the treat-
ment advice was changed for 33% of patients by the Dutch team.
Both without and with knowing the MammaPrint results 44/102
(43%) of patients were advised adjuvant chemotherapy by the
Belgian team. However, for 22% of patients the treatment advice
was changed because of MammaPrint (equal number of patients
changed from chemotherapy to no chemotherapy and vice versa).
Without knowing theMammaPrint results 94/158 (59%) of patients
were advised adjuvant chemotherapy by the Italian team. After
knowing the MammaPrint results, there was an increase of 13% in
adjuvant chemotherapy treatment advise (115/158 73%). Overall
the treatment advice was changed for 28% of patients by the Italian
team. Without knowing the MammaPrint result 117/194 (60%) of
patients were advised adjuvant chemotherapy by the Spanish team.
After knowing the MammaPrint results, there was a decrease of 2%
in adjuvant chemotherapy treatment advise (114/194 59%). Overall
the treatment advice was changed for 27% of patients by the
Spanish team.
A subgroup analysis in patients with ERþ/HER2 breast cancer
indicated that adjuvant chemotherapy treatment advice after
disclosure of the MammaPrint results was changed for 37% of pa-
tients by the Dutch team (a 21% reduction in advising chemo-
therapy), for 24% of patients by the Belgian team (equal number of
patients changed from chemotherapy to no chemotherapy and vice
versa), for 28% of patients by the Italian team (a 14% increase in
advising chemotherapy) and for 35% of patients by the Spanish
team (a 2% reduction in advising chemotherapy) (Table 3). Overall,
MammaPrint increased the inter-institutional agreement in adju-
vant chemotherapy/no chemotherapy treatment advice for patients
from 57% to 79% (Fig. 1A) and in patients with ERþ/HER2 breast
Table 3












CT advised 44 29 37/100 (37%)
CT not advised 8 19
Belgium
(n ¼ 82)
CT advised 17 10 20/82 (24%)
CT not advised 10 45
Italy
(n ¼ 120)
CT advised 54 8 22/120 (28%)
CT not advised 25 33
Spain
(n ¼ 151)
CT advised 46 28 53/151 (35%)
CT not advised 25 52
Overall
(n ¼ 453)
CT advised 161 75 143/453 (32%)














55 (23e70) 55 (27e70) 59 (26e68) 56 (25e69)
Tumor size, n
<1 cm 1 8 5 14
1e<2 cm 31 47 27 105
2e5 cm 33 34 2 69
>5 cm 0 3 1 4
Unknown 1 0 1 2
Grade, n
I 20 23 1 44
II 29 50 21 100
III 17 19 14 50
ER (IHC), n
Positive 54 81 32 167
Negative 12 11 4 27
HER2 (IHC), n
Positive 8 15 1 24
Negative 58 77 35 170
ER/PR/HER2, n 7 8 4 19
Lymph nodes, n
0 37 65 27 129
1e3 29 27 7 63
Unknown 0 0 2 2
Chemotherapy, n
Yes 48 38 17 103
No 18 54 19 91
Hormonal therapy, n
Yes 42 79 13 134
No 24 13 23 60
MammaPrint, n
Low Risk 32 33 20 85
High Risk 34 59 16 109
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC,
immunohistochemistry; PR, progesterone receptor.
P.G. Cusumano et al. / The Breast 23 (2014) 423e428 425cancer, MammaPrint increased the inter-institutional agreement
from 51% to 75% (Fig. 1B).
Adjuvant chemotherapy advise in ERþ/HER2 breast cancer
was also analyzed by subgroups including age (<40, 40e55 and
>55 years of age), tumor size (<1, 1e2, and >2 cm), tumor grade
(grade 1e3), and nodal status (N0 and N1). In all subgroups
analyzed, a higher proportion of MammaPrint High Risk patients
were advised chemotherapy compared withMammaPrint Low Risk
patients (Fig. 2). MammaPrint reduced chemotherapy recommen-
dation in the following subgroups: <40 and 40e55 years, grade 3,
>2 cm and N1. Chemotherapy recommendationwas equal (5%) in
the following subgroups:>55 years, grade 1 and 2, 1e2 cm, and N0.
MammaPrint increased chemotherapy recommendation in <1 cm.
In all subgroups analyzed the proportion of High Risk patientsTable 2












CT advised 67 30 42/128 (33%)
CT not advised 12 19
Belgium
(n ¼ 102)
CT advised 35 11 22/102 (22%)
CT not advised 11 45
Italy
(n ¼ 158)
CT advised 84 10 41/158 (26%)
CT not advised 31 33
Spain
(n ¼ 194)
CT advised 89 28 53/194 (27%)
CT not advised 25 52
Overall
(n ¼ 582)
CT advised 275 79 158/582 (27%)
CT not advised 79 149
CT, chemotherapy.versus Low Risk patients who were recommended chemotherapy
increased with MammaPrint.
In patients with HER2þ breast cancer, adjuvant chemotherapy/
no chemotherapy treatment advice with the MammaPrint results
was changed for 25% of patients by the Dutch team, for 11% of
patients by the Belgian team, for 35% of patients by the Italian team
and for none of the patients by the Spanish team. In patients with
ER breast cancer, adjuvant chemotherapy/no chemotherapy
treatment advice with the MammaPrint results was changed for 7%
of patients by the Dutch team, for 13% of patients by the Belgian
team, for 4% of patients by the Italian team and for none of the
patients by the Spanish team.
Discussion
This is the first pan-European study on the impact of Mam-
maPrint on clinical decision making for patients with breast cancer.
The results demonstrate the high variability in adjuvant treatment
strategies for breast cancer betweenmultidisciplinary teams at four
hospitals in four European countries based on traditional patient-
and tumor-related parameters. In similar populations of patients
the advice for adjuvant chemotherapy differs markedly across 4
European countries ranging from 45% in Belgium to 76% in the
Netherlands. Using MammaPrint would increase the agreement in
adjuvant treatment decisions between European hospitals for the
same patient cohort from 57% to 79%. The decision whether or not
to advise chemotherapy after disclosure of the MammaPrint results
was changed for 22% to 33% of patients by the multidisciplinary
teams of the 4 European hospitals. In patients with ERþ/HER2
breast cancer, the adjuvant chemotherapy treatment advice pro-
vided after disclosure of the MammaPrint results was changed for
24% to 37% of patients leading to an increased inter-institutional
agreement (51% to 75%).
Most patients with MammaPrint High Risk results were rec-
ommended adjuvant chemotherapy, whereas less than 20% of pa-
tients with MammaPrint Low Risk results were recommended
chemotherapy (except for patients <40 years, grade 3 and N1).
The differences in adjuvant treatment strategies for breast
cancer between the countries are most likely due to the differing
recommendations in the national guidelines of the Netherlands
[26], Belgium [27,28], Italy [29] and Spain [30]. The national
guidelines vary in their selection criteria of which patients should
receive adjuvant chemotherapy. In Belgium and Spain, MammaP-
rint only altered chemotherapy treatment advice for ERþ/HER2
patients. In the Netherlands, according to the CBO guidelines [26],
ER and HER2þ patients with small tumors (1 cm) do not receive
adjuvant chemotherapy. MammaPrint had an impact on the
treatment advice given to these patients. In Italy, MammaPrint did
not alter the treatment advice for ER patients (only one of 23 ER
Fig. 1. Inter-institutional agreement in treatment advice for the same patient cohort all patients (A) and for patients with ERþ/HER2 breast cancer (B).
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the subset of HER2þ patients, treatment was changed as a result of
MammaPrint in 35% of patients. In Spain, all HER2þ patients
receive chemotherapy; therefore MammaPrint had no impact on
the treatment advice provided for these patients.
Our results on the impact of MammaPrint on adjuvant treat-
ment decisions are similar to those of a Spanish study that inves-
tigated the impact of the 21-gene tumor expression profile
Oncotype DX on adjuvant treatment recommendations in 107
women with ER þ node-negative breast cancer [31]. In this study,
the use of Oncotype DX changed the recommended treatment in 34
of 107 (32%) women. The initial recommendation was changed
from chemotherapy plus hormonal therapy to hormonal therapy in
22 patients and from hormonal to chemotherapy plus hormonal
therapy in 12 patients.
The variation in treatment advice between institutions and
countries in our study is similar to that reported by Bueno-de-
Mesquita et al. in a retrospective review of two patient cohorts
from 18 hospitals in the Netherlands [23]. They reported a signifi-
cant difference in grade, ER status, HER2 status and clinicopatho-
logical risk between hospitals due to inter-observer variation in the
pathological examination and a resultant difference in the adjuvant
treatment advice provided [24]. If clinical risk had been assessed
according to Dutch guidelines or Adjuvant! Online, 15% or 8% of
patients, respectively, would have been assigned to a different
clinical risk group and thus received different adjuvant treatment
advice.
The ideal molecular test should be reproducible and reliable,
should have data that are validated both for prognostic and pre-
dictive power, should be independent of receptors status and
treatment compliance and must provide a definite result [32].
The prognostic power of MammaPrint has been confirmed in
multiple studies [12e18]. The predictive value of MammaPrint for
chemotherapy benefit in addition to endocrine therapy has been
analyzed from pooled study series [33]. For patients (n ¼ 252) who
were identified MammaPrint Low Risk, receiving endocrine treat-
ment alone and endocrine after chemotherapy was statistically
insignificant (p ¼ 0.200). By contrast, 289 patients who wereidentified asMammaPrint High Risk benefitted from the addition of
chemotherapy to endocrine treatment (p < 0.010). The absolute
benefit was 12% [33]. MammaPrint was also tested in the neo-
adjuvant setting as a predictive test for chemotherapy [34]. Of the
167 patients, 23 (14%) were MammaPrint Low Risk, but none
showed pathologic complete remission (pCR) in the breast and
axilla. By contrast, among 144 (86%) patients who were Mam-
maPrint High Risk, 29 (20%) achieved pCR. MammaPrint High Risk
was significantly associated with pCR (p ¼ 0.015). Thus, a pCR is
unlikely to be achieved in patients with tumors that have a Low
Risk MammaPrint, whereas patients with High Risk tumors are
sensitive to chemotherapy [34].
MammaPrint has been shown to be a cost-effective strategy to
guideadjuvantchemotherapy treatment inanumberof studiesusing
a Markov model [35e37]. Using a model with three health states;
Chen et al. compared the cost effectiveness of MammaPrint and
Adjuvant! Online [35]. In the base-case model, MammaPrint reclas-
sified 29% of patients and resulted in 10% more patients avoiding
chemotherapy. Compared with Adjuvant! Online, MammaPrint was
associatedwith ahigher total cost perpatientof $1,440 and increased
life expectancy by 0.14 year or 0.15 quality-adjusted life-year (QALY).
The incremental cost-effectiveness ratio was approximately $10,000
per life-year or QALY, which is within the range generally considered
to be cost-effective for a diagnostic or therapeutic intervention. In a
comparison of MammaPrint with the St Gallen guidelines and
Adjuvant! Online for early breast cancer, quality-adjusted survival
was found to be longer with MammaPrint (12.44 versus 12.20 and
11.24QALYs, respectively),whichhad thehighest probabilityof being
cost-effective for a willingness to pay for a QALY >V4,600, based on
costs per QALY [36]. Comparedwith Oncotype DX,MammaPrintwas
more cost effective at a threshold willingness-to-pay of $50,000 per
QALYandwas associatedwith a per-patient cost of $21,598 for a gain
of 7.461 QALYs versus a per-patient cost of $27,882 for a gain of 7.364
QALYs with Oncotype DX [37].
Although outcome data of the randomized prospective MIND-
ACT study has not been published MammaPrint and Oncotype DX
have been included in the St. Gallen and ESMO clinical practice
guidelines to gain additional prognostic and/or predictive
Fig. 2. Proportions of patients receiving chemotherapy by MammaPrint category and age group (A), tumor size (B), grade (C), and nodal status (D).
P.G. Cusumano et al. / The Breast 23 (2014) 423e428428information to complement pathology assessment and to predict
response to adjuvant chemotherapy, in particular in patients with
ERþ and HER2 early breast cancer [2,19].
In conclusion, the use of MammaPrint to classify patients as Low
or High Risk increased the inter-institutional agreement for adju-
vant chemotherapy treatment advice from 57% to 79% for the
overall patient population and from 51% to 75% for patients with
ERþ/HER2 breast cancer. The impact of MammaPrint on the
change in adjuvant treatment advice for patients with ERþ/HER2
breast cancer, the patient group with the highest MammaPrint
clinical utility, ranged from 24% to 37% in this European study.
MammaPrint can decrease the inter-institutional and inter-country
variability in the adjuvant treatment advice provided to female
patients with breast cancer.
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